Biocon Biologics Managing Director and CEO Shreehas Tambe says the board has not recommended any action on a potential IPO or merger of the biosimilars unit. He shares his perspective on Bloomberg’s Insight with Haslinda Amin. (Source: Bloomberg)
www.bloomberg.com
#Biocon #Biologics #CEO #Discusses #Merger #IPO #Plans
Biocon Biologics CEO Discusses Merger and IPO Plans
